Affecting roughly half a million Americans each year, bacterial infections caused by Clostridioides difficile - commonly known as C. diff - are a serious and persistent problem for patients and ...
Acurx's Program in the Broader CDI Patient Population is Ready to Advance toPhase 3 International Clinical Trials Acurx previously announced that it had received positive regulatory guidance from the ...
A novel vaccination approach developed by Vanderbilt Health researchers cleared the harmful gut bacterium Clostridioides difficile (C. diff) in an animal model of infection. An experimental vaccine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results